Otherwise, this looks like a fantastic growth stock that just doubled its addressable market with the Zava acquisition. Today ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

By Amina Niasse (Reuters) -Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up ...

Hims & Hers leverages ZAVA's expertise to enter Europe's weight-loss market, boosting growth and profitability. Read what ...

The past six months have been a windfall for Hims & Hers Health’s shareholders. The company’s stock price has jumped 90%, ...

Hims & Hers Health has seen massive success, aided by the growing use of GLP-1 drugs. Click here to find out why I downgrade ...

Per the chart above, roughly 35% of Hims & Hers float is sold short. Investors who short a stock are betting its price will fall. Short interest of 10% or more is considered unusually high. Not only ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Hims & Hers Health, Inc. (HIMS) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look ...

Hims & Hers (NYSE: HIMS) stock, a prominent player in the booming telehealth sector, has undeniably captured significant investor attention recently. Perhaps you, like many others, have been caught up ...

Hims & Hers Health Inc (NYSE:HIMS) stock fell 3.8% Tuesday after Eli Lilly and Company (NYSE:LLY) indicated it would not partner with telehealth firms selling copycat versions of weight-loss drugs, ...

In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $55.25, denoting a -2.83% change from the preceding trading day.